What changed: IDH1- and IDH2-mutated acute myeloid leukaemia
Every dated change on the records linked to IDH1- and IDH2-mutated acute myeloid leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval5Trial result2Milestone4This record1
September 2026 · 1
2022 · 4
- 2022ApprovalIvosidenibIvosidenib approved in US
Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)
- 2022ApprovalOlutasidenibOlutasidenib approved in US
Relapsed/refractory IDH1-mutated AML
- 2022Trial resultAGILEAGILE reported
OS 24.
- 2022MilestoneAGILEAGILE: ivosidenib plus azacitidine lengthens life in newly diagnosed unfit patients; olutasidenib approved
A milestone in how this cancer is treated.